Interpreting conjugated bilirubin levels in newborns

Area of Science:

• Neonatal Medicine
• Pediatric Gastroenterology
• Clinical Chemistry

Background:

• Elevated conjugated bilirubin (CB) in newborns is a clinical concern.
• Understanding the significance of CB levels is crucial for timely diagnosis and management.
• Distinguishing between different causes of hyperbilirubinemia is essential for appropriate infant care.

Purpose of the Study:

• To determine the clinical significance of elevated conjugated bilirubin (CB) levels in newborns.
• To correlate CB and direct bilirubin (DB) levels with specific diagnoses in neonates.
• To establish thresholds for further investigation based on CB levels.

Main Methods:

• Retrospective analysis of a large birth cohort (271,186 newborns) from 1995-2004.
• Utilized a hospital network database for CB and DB levels.
• Correlated bilirubin levels with International Classification of Diseases, 9th Revision diagnoses.

Main Results:

• The 99th percentile for CB is 0.5 mg/dL; for DB, it is 2.1 mg/dL.
• CB levels between 0.5-1.9 mg/dL are often unexplained but can be linked to infection.
• For CB ≥5 mg/dL, 47% of newborns had biliary disease and 43% had liver disease.

Conclusions:

• Conjugated bilirubin (CB) and direct bilirubin (DB) levels are not interchangeable.
• Newborns with CB ≥0.5 mg/dL and <2 mg/dL require infection evaluation and observation.
• Newborns with CB ≥2 mg/dL need comprehensive hepatobiliary system assessment.